Compare
AIM ImmunoTech Inc. vs VivoSim Labs, Inc. vs Inmune Bio, Inc. vs Zivo Bioscience, Inc.
| Latest fiscal year | AIM ImmunoTech Inc. AIM | VivoSim Labs, Inc. VIVS | Inmune Bio, Inc. INMB | Zivo Bioscience, Inc. ZIVOLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2024-12-31 |
| Revenue | $88.0K | $131.0K | $50.0K | $157.2K |
| Revenue growth (YoY) | -48.2% | -9.0% | +257.1% | +468.6% |
| Gross margin | n/a | n/a | n/a | 31.1% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$13.96M | -$13.84M | -$45.93M | -$13.38M |
| EPS (Diluted) | -$8.62 | -$5.35 | -$1.86 | -$4.23 |
| Operating cash flow | -$10.96M | -$10.83M | -$22.58M | -$4.31M |
| Free cash flow | n/a | -$10.83M | -$23.62M | n/a |
| Cash & equivalents | $2.98M | $5.02M | $24.75M | n/a |
| Total assets | $5.78M | $7.39M | $32.35M | $1.64M |
| Total liabilities | $15.56M | $8.48M | $8.83M | $2.16M |
| Shareholders' equity | -$9.78M | -$1.10M | $23.52M | -$514.9K |
| Return on year-end equity | n/a | n/a | -195.3% | n/a |
| Shares outstanding | 3.07M | 2.89M | 26.59M | 3.62M |
Revenue, most recent five fiscal years
| Fiscal year | AIM ImmunoTech Inc. | VivoSim Labs, Inc. | Inmune Bio, Inc. | Zivo Bioscience, Inc. |
|---|---|---|---|---|
| Latest | $88.0K Ended 2025-12-31 | $131.0K Ended 2026-03-31 | $50.0K Ended 2025-12-31 | $157.2K Ended 2024-12-31 |
| 1 year earlier | $170.0K Ended 2024-12-31 | $144.0K Ended 2025-03-31 | $14.0K Ended 2024-12-31 | $27.6K Ended 2023-12-31 |
| 2 years earlier | $202.0K Ended 2023-12-31 | $109.0K Ended 2024-03-31 | $155.0K Ended 2023-12-31 | $0 Ended 2022-12-31 |
| 3 years earlier | $141.0K Ended 2022-12-31 | $370.0K Ended 2023-03-31 | $374.0K Ended 2022-12-31 | $0 Ended 2021-12-31 |
| 4 years earlier | $135.0K Ended 2021-12-31 | $1.50M Ended 2022-03-31 | $181.0K Ended 2021-12-31 | $20.0K Ended 2020-12-31 |